Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Diuretics × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1 Immunoglobulin Light-chain Amyloidosis 1 Essential Hypertension 1 Breast Neoplasms 1

Interventions

pembrolizumab 182 Gemcitabine 168 Paclitaxel 152 Carboplatin 137 Bevacizumab 128 Surveys and Questionnaires 118 Docetaxel 114 Cisplatin 114 Cyclophosphamide 109 Blood Specimen Collection 109 Exercise 107 Nivolumab 98 Fluorouracil 89 Capecitabine 86 Dexamethasone 81 Radiotherapy 80 Irinotecan 74 Pemetrexed 68 Oxaliplatin 68 Standard of Care 66 Leucovorin 64 Drug Therapy 64 Cetuximab 60 Erlotinib Hydrochloride 56 Sorafenib 53 atezolizumab 52 Ipilimumab 50 Doxorubicin 50 trametinib 47 Interviews as Topic 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02215733 2014-08-13

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Boehringer Ingelheim

1,165,781 enrolled

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡